18th Feb 2020 13:14
(Alliance News) - Nuformix PLC said Tuesday it has appointed Karl Keegan as a non-executive director with immediate effect.
The pharmaceutical development company said Keegan is currently chief executive officer at HOX Therapeutics Ltd, a private biotechnology company developing cancer therapies based on HOX genes.
"He spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada," the company said.
Dan Gooding, chief executive officer, said: "With his extensive experience in strategy, finance, corporate development and capital markets within life sciences, Karl brings a wealth of experience that is highly relevant to Nuformix at this moment as we enter new stages in the development of the company and our assets."
At the beginning of February the company announced resignation of Non-Executive Chair Dave Tapolczay with immediate effect. Non-Executive Director Christopher Blackwell assumed the role of interim chair.
At the end of January Nuformix also announced resignation of Non-Executive Director John Lidgey.
Nuformix shares were trading 0.7% higher in London at 6.80 pence each on Tuesday.
By Loreta Juodagalvyte; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Nuformix